Market Cap 630.35M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 50.06
Forward PE 47.21
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 586,000
Avg Vol 481,738
Day's Range N/A - N/A
Shares Out 40.62M
Stochastic %K 65%
Beta 1.33
Analysts Sell
Price Target $23.33

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 314 6297
Address:
1050 Waltham Street, Suite 302, Lexington, United States
JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS wrong board lol
0 · Reply
JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS do it
0 · Reply
Ss532
Ss532 Aug. 21 at 7:40 PM
$KROS https://www.investing.com/news/company-news/adar1-urges-keros-board-to-engage-on-strategy-after-meeting-refusal-93CH-4204618
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 12:33 PM
$KROS ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment https://www.prnewswire.com/news-releases/adar1-sends-open-letter-to-keros-board-of-directors-urging-the-board-to-engage-constructively-on-strategy-capital-allocation-and-board-refreshment-302535332.html "Additionally, we are concerned by the lack of follow-through on the Company's June 9 announcement regarding the planned return of $375 million in excess capital. Shareholders have now waited for more than two months without any update on the timing or process for the return of capital. We urge the Company to promptly communicate a clear and detailed plan to return capital, specifically through the declaration of a special dividend." ADAR1 reported beneficial ownership of 5,389,264 shares of KROS in a 13F filed on Aug 14.
1 · Reply
YoloAlfred
YoloAlfred Aug. 21 at 10:39 AM
$KROS 🤔
0 · Reply
topstockalerts
topstockalerts Aug. 20 at 2:50 PM
$KROS testing support....
0 · Reply
MBSB
MBSB Aug. 20 at 2:26 PM
$KROS https://www.marketbeat.com/instant-alerts/filing-40245-shares-in-keros-therapeutics-inc-nasdaqkros-purchased-by-tejara-capital-ltd-2025-08-15/
0 · Reply
MBSB
MBSB Aug. 20 at 2:24 PM
$KROS https://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-has-131-million-stake-in-keros-therapeutics-inc-nasdaqkros-2025-08-17/
0 · Reply
Mamma_m1a
Mamma_m1a Aug. 20 at 1:54 PM
$SRPT Keros Announces FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy $KROS
0 · Reply
CycleTrade
CycleTrade Aug. 14 at 6:56 PM
$KROS Keras Thera a strong showing under the big top
0 · Reply
Latest News on KROS
Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 4 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value


Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 5 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump


Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 5 months ago

Keros Therapeutics adopts 'poison pill' plan


Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 5 months ago

Keros Therapeutics Announces Review of Strategic Alternatives


JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS wrong board lol
0 · Reply
JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS do it
0 · Reply
Ss532
Ss532 Aug. 21 at 7:40 PM
$KROS https://www.investing.com/news/company-news/adar1-urges-keros-board-to-engage-on-strategy-after-meeting-refusal-93CH-4204618
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 12:33 PM
$KROS ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment https://www.prnewswire.com/news-releases/adar1-sends-open-letter-to-keros-board-of-directors-urging-the-board-to-engage-constructively-on-strategy-capital-allocation-and-board-refreshment-302535332.html "Additionally, we are concerned by the lack of follow-through on the Company's June 9 announcement regarding the planned return of $375 million in excess capital. Shareholders have now waited for more than two months without any update on the timing or process for the return of capital. We urge the Company to promptly communicate a clear and detailed plan to return capital, specifically through the declaration of a special dividend." ADAR1 reported beneficial ownership of 5,389,264 shares of KROS in a 13F filed on Aug 14.
1 · Reply
YoloAlfred
YoloAlfred Aug. 21 at 10:39 AM
$KROS 🤔
0 · Reply
topstockalerts
topstockalerts Aug. 20 at 2:50 PM
$KROS testing support....
0 · Reply
MBSB
MBSB Aug. 20 at 2:26 PM
$KROS https://www.marketbeat.com/instant-alerts/filing-40245-shares-in-keros-therapeutics-inc-nasdaqkros-purchased-by-tejara-capital-ltd-2025-08-15/
0 · Reply
MBSB
MBSB Aug. 20 at 2:24 PM
$KROS https://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-has-131-million-stake-in-keros-therapeutics-inc-nasdaqkros-2025-08-17/
0 · Reply
Mamma_m1a
Mamma_m1a Aug. 20 at 1:54 PM
$SRPT Keros Announces FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy $KROS
0 · Reply
CycleTrade
CycleTrade Aug. 14 at 6:56 PM
$KROS Keras Thera a strong showing under the big top
0 · Reply
CyberCuba
CyberCuba Aug. 13 at 7:44 PM
$KROS An independent director now being the board chair sanitizes issues for a buyout versus insider in the same position. Stay tuned.
0 · Reply
Puffyk
Puffyk Aug. 13 at 4:13 PM
$KROS Run to $25-$35 by end of year. the set up is spectacular
1 · Reply
Robotchicken
Robotchicken Aug. 13 at 1:33 PM
$KROS I am bailing, too much money to be made in this market. Blessings to all.
1 · Reply
Robotchicken
Robotchicken Aug. 8 at 1:46 PM
$KROS fatigue kicking in
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 11:00 AM
HC Wainwright & Co. updates rating for Keros Therapeutics ( $KROS ) to Buy, target set at 25 → 20.
0 · Reply
buyandsold
buyandsold Aug. 7 at 6:41 PM
$KROS is the P2 worth $4?
0 · Reply
buyandsold
buyandsold Aug. 7 at 6:40 PM
$KROS brutal today, people fed up to wait
0 · Reply
CipherGain
CipherGain Aug. 7 at 4:37 AM
0 · Reply
d_risk
d_risk Aug. 6 at 9:10 PM
$KROS - Keros Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors Keros updates risk factors in 2025 emphasizing clinical and regulatory uncertainties for KER-065 and elritercept, dependence on key patents and collaborations, intensified IP litigation risks, manufacturing and trial outsourcing vulnerabilities, corporate restructuring costs, evolving tax and compliance burdens, stock volatility and shareholder concentration concerns, plus new anti-takeover provisions and potential limits on capital returns. #Biotechnology #CorporateRestructuring #RegulatoryRisk #IntellectualProperty #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KROS/10-Q/2025-08-06
0 · Reply
buyandsold
buyandsold Aug. 5 at 2:22 AM
$KROS when and how are we getting our $9. I would not be surprised to hear they have changed their minds.
1 · Reply
Smokey_The_Bear
Smokey_The_Bear Aug. 5 at 1:10 AM
0 · Reply
ChessGM
ChessGM Aug. 2 at 3:22 AM
$KROS "Heads up alert! Upcoming earnings on Tuesday, 8/5/2025 for $KROS Neutral (5.2) Financial Analysis Keros Therapeutics (KROS) is positioned within the biotechnology sector, focusing on developing therapeutics for disorders related to the TGF-ß family of proteins. The recent milestone of dosing the first patient in the Phase 3 RENEW trial for Elritercept signifies progress in their clinical pipeline, triggering a $10 million payment under their global license agreement with Takeda. This development underscores Keros' commitment to advancing its therapeutic candidates through clinical trials, potentially enhancing its future revenue streams. Analyzing KROS's financial metrics, the company's P/E ratio is not applicable as it is still in the clinical stage and not yet profitable. Its EPS growth remains negative, reflecting the ongoing investment in R&D and clinical trials. Compared to industry peers like Rocket Pharmaceuticals and Krystal Biotech, Keros shows similar characteristics of high R&D expenditure and a focus on pipeline advancement rather than immediate profitability. Revenue forecasts for Keros are speculative at this point, heavily reliant on successful trial outcomes and subsequent regulatory approvals. Earnings Report and Expectations Upcoming earnings reports for Keros are anticipated to provide further insights into their financial health and clinical progress. Historically, the company has reported significant R&D expenditure, consistent with its business model as a clinical-stage biotech firm. Analyst consensus estimates suggest continued investment in clinical trials, with expectations for incremental revenue growth contingent on successful trial outcomes and potential partnerships or licensing agreements. The impact of these reports on the stock is likely to hinge on both clinical trial updates and financial spending efficiency. Sector Performance The biotechnology sector, encompassing companies like Keros, is characterized by high volatility and significant dependency on clinical trial outcomes and regulatory approvals. Currently, the sector is observing a mixed performance with some companies experiencing significant stock price increases following positive trial results, as seen with Rhythm Pharmaceuticals and Rocket Pharmaceuticals. This highlights the sector's potential for substantial returns amid inherent risks, as firms navigate through regulatory pathways and strive for successful therapeutic developments. - Funds were net buyers of $KROS during the previous reporting quarter. - Funds with large holdings in $KROS include: - Nantahala Capital Management LLC, MV: $15MM. Fund Rank: 67% www.nantahalapartners.com - OrbiMed Advisors LLC, MV: $10MM. Fund Rank: 55% www.orbimed.com - Alkeon Capital Management LLC, MV: $9MM. Fund Rank: 94% www.alkeoncapital.com - Redmile Group LLC, MV: $6MM. Fund Rank: 55% www.redmilegroup.com - PDT Partners LLC, MV: $3MM. New position. Fund Rank: 89% www.pdtpartners.com - Last 10 days performance: 4% - Last 30 days performance: 7% - Last 90 days performance: -2% Some of the latest news articles: - Title: KROS vs. EXAS: Which Stock Should Value Investors Buy Now? Publication Date: 7/28/2025 3:40:04 PM, Source: yahoo URL: https://finance.yahoo.com/news/kros-vs-exas-stock-value-154004166.html?.tsrc=rss - Title: RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure Publication Date: 7/18/2025 3:28:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/rckt-stock-fdas-rmat-tag-152800831.html?.tsrc=rss - Title: Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept Publication Date: 7/17/2025 12:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/keros-therapeutics-announces-first-patient-120000028.html?.tsrc=rss - Title: KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up Publication Date: 7/10/2025 4:10:00 PM, Source: yahoo Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."
0 · Reply